Orthocell (OCC) Investor presentation summary

Commercial progress and financial position

• Remplir US market launch is progressing as planned, with sales building and market access activities on track.

• Achieving cash breakeven in the US requires less than 1% market share, or about 10,000 units annually.

• Revenue has shown consistent growth over the last three halves, driven by device sales.

• The company is fully funded for growth, with cash reserves expected to remain above the high $20Ms.

• Manufacturing expansion is underway to quadruple capacity and reduce unit costs.

Strategic vision and operational focus

• Aims to lead regenerative medicine innovation and target ASX 300 inclusion through disciplined growth.

• Strategic priorities include expanding in the Americas, growing in Asia-Pacific, and advancing the product pipeline.

• FY26 focus is on US market access, Asia expansion, UK/EU launch planning, and recruiting specialist talent.

• Investments are being made in people, commercial leadership, and automation to support scalable growth.

US market opportunity and execution

• Over 700,000 peripheral nerve repair procedures occur annually in the US, with devices used in only ~10%.

• Remplir targets a niche, aiming for less than 1% of the market to reach breakeven.

• Market access funnel includes regulatory, commercial, awareness, contract, onboarding, and loyalty stages.

• As of Jan 2026, 71 VAC submissions, 27 approvals, 19 customers, and ~70% repeat usage rate.